medRxiv preprint doi: https://doi.org/10.1101/2024.01.17.24301423; this version posted March 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1 2	Clinical Characteristics and Factors Associated with Long COVID in Zambia, August 2020 to January 2023: A Mixed Methods Design
3	Warren Malambo ¹ *, Duncan Chanda ^{2,3} ,Lily Besa ³ , Daniella Engamba ^{2,3} , Linos Mwiinga ¹ , Mundia
4	Mwitumwa ² , Peter Matibula ² , Neil Naik ² , Suilanji Sivile ^{2,3} , Simon Agolory ¹ , Andrew Auld ¹ , Lloyd
5	Mulenga ³ , Jonas Z. Hines ^{1,¶} , Sombo Fwoloshi ^{2,3,¶}
6	¹ U.S. Centers for Disease Control and Prevention, Division of Global HIV/TB, Lusaka, Zambia
7	² University Teaching Hospital Adult and Emergency Hospital, Department of Internal Medicine,
8	Lusaka, Zambia
9	³ Ministry of Health, Lusaka, Zambia
10	
11	
12	* Corresponding author:
13	Email: ykh1@cdc.gov (WM)
14	
15	¹ These authors contributed equally to this work.
16	
17	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.17.24301423; this version posted March 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

18 Abstract

19 Introduction

- 20 A number of seroprevalence studies in Zambia document the extent of spread of SARS-CoV-2, yet
- 21 few have examined signs, symptoms and conditions that continue or develop after acute COVID-19
- 22 infection (long COVID). This is an important gap given the estimated prevalence of long COVID in
- 23 other countries. We sought to examine characteristics of post-acute COVID-19 (PAC-19) clinics
- 24 patients in Zambia and assess factors associated with long COVID at first visit to a PAC-19 clinic and
- 25 longitudinally among a cohort of patients.

26 Methods

- 27 Long COVID was defined, initially in the Zambia PAC-19 clinical guidelines, as new, relapsing, or
- 28 persistent symptoms lasting >4 weeks after an initial SARS-CoV-2 infection. Severe COVID-19 was
- 29 defined as COVID-19 episode that required supplemental oxygen therapy, intensive care unit stay or
- 30 treatment with steroids/remdesivir. We performed a cross-sectional and longitudinal analysis of
- 31 PAC-19 clinic patients from August 2020 to January 2023 using logistic and mixed effects regression
- 32 models and considered statistical significance at p<0.05.

33 Results

- In total, 1,359 patients attended PAC-19 clinics of whom 548 (40.3%) with ≥2 visits were included in
- 35 the longitudinal analysis. Patients' median age was 53 (interquartile range [IQR]: 41-63) years, 919
- 36 (67.6%) were hospitalized for acute COVID-19, and of whom 686 (74.6%) had severe COVID-19.
- 37 Patients with hospital length of stay ≥15 days (adjusted odds ratio [aOR]: 5.37; 95% confidence
- 38 interval [95% CI]: 2.99-10.0), severe illness (aOR: 3.22; 95% CI: 1.68-6.73), and comorbidities
- 39 (aOR:1.50; 95% CI: 1.02-2.21) had significantly higher likelihood of long COVID. Longitudinally, long
- 40 COVID prevalence significantly (p<0.001) declined from 75.4% at the first PAC-19 visit to 26.0% by
- 41 the fifth visit. The median follow-up time was 7 (IQR: 4-12) weeks.

42 Conclusion

- 43 Long COVID symptoms were common among patient presenting for care in PAC-19 clinics in Zambia,
- 44 but most recovered within ~2 months. Despite potentially substantial morbidity due to long COVID,
- 45 few patients overall with COVID-19 attended a PAC-19 clinic. Scaling up PAC-19 services and
- 46 integrating into routine clinical care could improve access by patients.

47

48 Introduction

Since the identification of the first SARS-CoV-2 infections in December 2019, the Coronavirus disease 2019 (COVID-19) has become a major public health problem. Its morbidity and mortality dramatically increased across countries and regions leading to its classification as a pandemic [1]. As of February 2024, the World Health Organization (WHO) had reported over 774 million cumulative COVID-19 cases and over 7 million cumulative COVID-19 deaths globally [2]. In the Africa region alone, over 9.5 million cumulative COVID-19 cases and over 175 thousand COVID-19 deaths were reported for the same time period.

56 People infected with SARS-CoV-2 commonly develop symptoms within 4-5 days following exposure 57 although others may be asymptomatic [3]. Acute COVID-19 (within 4 weeks from the initial SARS-CoV-2 58 infection) presents with as a multi-system cluster of symptoms, i.e., general, cardiovascular, pulmonary, 59 gastrointestinal, neurologic, musculoskeletal, and ear, nose, and throat. Recovery from COVID-19 for 60 most patients occurs within 7-10 days after symptoms onset but could take weeks to months in some 61 patients [4-7]. Previous epidemics such the 2003 severe acute respiratory syndrome (SARS) and the 62 2012 Saudi Arabia Middle East respiratory syndrome coronavirus (MERS-CoV) had patients who 63 presented with persistent symptoms post-acute infection [8-11]. Their symptoms included fatigue, 64 decreased quality of life, shortness of breath and behavior health problems that impacted on their 65 health-related quality of life.

66 Symptoms and conditions that continue or develop after acute COVID-19 infection are variably named 67 (post-acute COVID-19, post-acute sequelae of SARS-CoV-2 infection, post-COVID conditions, long-haul 68 COVID, post-COVID conditions, long-term effects of COVID and chronic COVID) but are also referred to 69 as long COVID [6, 12]. Commonly reported long COVID symptoms include fatigue, fever, cough, 70 dizziness, brain fog, and myalgia although symptoms are varied and potentially have overlapping 71 etiologies [13-15]. Long COVID is thus a syndrome characterized by persistent, new, relapsing or 72 delayed SAR-CoV-2 symptoms ≥12 weeks beyond onset of the acute episode [12, 16-18], and can have a 73 protracted path to recovery that impacts on quality of life, earnings and health care costs [19-21]. As much as 77 million people around the world could be estimated to have long COVID, based on a 74 75 conservative estimated prevalence of 10% of reported number of infected people [2, 22]; the actual

number may likely be much higher given undocumented cases due to limited testing capacity. Among

- acute-COVID-19 outpatient cases, the prevalence of long COVID is estimated at 10-30%; 50-70% of
- hospitalized cases and 10-12% of vaccinated cases [22-27]. For example, a study of the burden,

- 79 causation, and particularities of long COVID in 7 African countries estimated a pooled long COVID
- 80 prevalence of 41% [28]. Long COVID is associated with increasing age, comorbidities, hospitalization for
- 81 acute COVID-19, severe COVID-19, and vaccination status [29-31]. Vaccination against SARS-CoV-2 is,
- 82 however, associated with reduced likelihood of severe COVID-19 and long COVID.

There's growing evidence on long COVID from countries in Africa [28, 32-34]. Disease severity and admission to the intensive care unit during acute COVID-19, for example, were found to be associated with long COVID in Nigeria and South Africa [35, 36]. Scoping studies on long COVID in Africa found comorbidities and age >40 years to be associated factors [33, 37]. In Zambia, 17% of persons with acute COVID-19 in July 2020 were found to be experiencing symptoms ~2 months later [38]. Zambia's reported COVID-19 cases are, however, likely an underestimate given limited testing capacity, asymptomatic infections, and mild clinically ill cases who may not have come to the attention of the health system [39-

90 41].

While a number of seroprevalence studies in Zambia document the extent of spread of SARS-CoV-2, few
have examined longer term outcomes such as long COVID [36, 39, 41-45]. This is an important gap given
the estimated prevalence of long COVID and extent of SARS-CoV-2 transmission in other countries in
Africa. In this study, we examined the characteristics of patients presenting for care in specialized postacute COVID-19 (PAC-19) clinics in Zambia and assessed factors associated with long COVID at first visit

to a PAC-19 clinic and longitudinally among a cohort of patients with \geq 2 PAC-19 clinic visits.

97 Methods

98 Study setting

99 Beginning August 2020, the Zambia Ministry of Health set up 13 specialized PAC-19 clinics to care for

- 100 people following SARS-CoV-2 infection, initially at the two national referral hospitals in Lusaka city, the
- 101 capital of Zambia, and subsequently at 11 other major hospitals across all 10 provinces of Zambia.

102 Study participants

Per national PAC-19 clinical guidelines, patients diagnosed with SARS-CoV-2 infection presented in PAC-19 clinics for follow-up care after discharge from hospital admission or outpatient episodic [46]. At the first PAC-19 clinic visit, patients' demographics, medical history, comorbidities, and current symptoms were recorded on a standardized paper form. Physical examinations and laboratory investigations were conducted based on patient's medical history as required. Patients' ability to perform activities, as part of examination of their functional and mental health status, were also evaluated.

- 109 Further clinical appointments of up to 5 review visits were at the clinicians' discretion. Symptoms were
- assessed by clinicians at each PAC-19 clinic visit on review of systems: general, cardiovascular,
- 111 pulmonary, urinary, neurologic, musculoskeletal, ear, nose, and throat (ENT), mental health concerns,

depression, anxiety, and dermatologic. Pre-existing comorbidities (hypertension, diabetes,

113 cardiovascular disease, cancer, chronic lung disease, kidney disease, or liver disease,

- immunosuppression, obesity, HIV and TB) were documented. Patients requiring further specialist care
- 115 were referred to various units including physiotherapy, cardiology, endocrinology, nephrology,
- psychiatry, and pulmonology. Anonymized data from patients standardized clinical paper forms were
- 117 routinely abstracted into an electronic database (REDCap v11.0.3); which was accessed on 5th January
- 118 2023 and analyzed for this study.

119 Study design

120 We implemented a mixed methods design to assess for factors associated with long COVID at first visit

- to a PAC-19 clinic and longitudinally across review visits. First, we performed a cross-sectional analysis of
- all PAC-19 clinic patients with data entered in the REDCap electronic databases from August 5, 2020,
- through to January 26, 2023. We then did a longitudinal sub-analysis of patients with ≥2 PAC-19 clinic
 review visits.

125 The longitudinal sub-analysis data structure included repeated observations of long COVID symptoms

- 126 and patient-level characteristics. Demographic and clinical characteristics of patients included time-
- 127 invariant covariates sex, age (patients repeatedly observed for <1 year), presence of newly diagnosed
- medical conditions, presence of pre-existing comorbidities, and acute COVID-19 episode details. Time-
- variant covariates included COVID-19 vaccination status and referral to specialist services.

130 Study variables and definitions

131 Long COVID was defined, initially in the Zambia post-acute COVID-19 guidelines, as new, relapsing or 132 persistent COVID-19 symptoms that lasted greater than 4 weeks after the initial SARS-CoV-2 infection 133 [46, 47]. Severe COVID-19 was defined as COVID-19 episode that required supplemental oxygen 134 therapy, intensive care unit (ICU) stay or treatment with steroids or remdesivir. Vaccination status categorization was based on vaccination records, when available, or patients' self-reported status. SARS 135 136 CoV-2 variants classification was based on the dominant variant at the time of SARS-CoV-2 diagnosis as 137 captured by the Zambia's genomic surveillance system and submitted to the Global Initiative on Sharing 138 All Influenza Data (GISAID) rather than sequenced specimens from patients [48]. Diabetes, hypertension,

- 139 or deep vein thrombosis/pulmonary embolism detected at the time of SARS-CoV-2 diagnosis were
- 140 categorized as newly diagnosed medical conditions.

141 Study size

- 142 For the study sample size, we assumed prevalence of long COVID at 30% and a precision corresponding
- to the effect size of 5%. The prevalence or Cochrane formula (described elsewhere) was used to
- 144 calculate the minimum sample size of 323 [49]. Study participants were included in the study if they
- 145 were COVID-19 patients presenting in PAC-19 clinics for follow-up care after discharge from hospital or
- 146 outpatient episodic care and had their information abstracted to the clinics' REDCap electronic
- 147 database. A full enumeration of all PAC-19 clinic attendees was however considered for higher accuracy
- 148 and precision. For the longitudinal sub-analysis, patients were excluded from the analysis if they
- 149 attended a PAC-19 clinic only once.

150 Statistical Analysis

- 151 At descriptive statistics we reported frequencies with proportions for categorical variables and medians
- 152 with the interquartile range (IQR) for non-normally distributed numeric variables assessed using the
- 153 Shapiro-Wilk test. The Pearson Chi-square and Kruskal Wallis tests for proportions and Wilcoxon rank
- sum test for medians were used to estimate the direction and magnitude of association. An unadjusted
- and adjusted logistic regression model was fitted to assess for factors associated with having long COVID
- 156 at first visit to a PAC-19 clinic.
- The main cross-sectional analysis was for patients hospitalized during acute COVID-19 (inpatients) to maintain key variables in the analysis. At multivariable analysis, we adjusted for age, presence of newly diagnosed medical conditions, presence of pre-existing comorbidities, and COVID-19 episode details (i.e., hospital length of stay, and presence of severe COVID-19). Covariate inclusion criteria at multivariable analysis were based on theoretical relevance to the study and statistical significance (pvalue≤0.2). We also conducted an additional cross-sectional analysis that included both inpatients and
- 163 outpatients during acute infection to assess for association of hospitalization during acute COVID-19
- 164 with long COVID.
- 165 For the longitudinal sub-analysis, we a fitted mixed effects model to account for the heterogeneity in
- 166 long COVID i.e., the differences between patients and within patients across repeated observations or
- 167 PAC-19 clinic visits. An unadjusted and adjusted mixed effects model was separately fitted for acute
- 168 COVID-19 inpatients only and additionally for both inpatients and outpatients. The patient was the
- 169 random effects term for the model. Since there was dependence in the data, we also reported the

- 170 conditional intraclass correlation (ICC) which quantified the variance in long COVID heterogeneity that
- 171 was attributable to between patients and within patients across PAC-19 visits.


Only covariates with <10% missingness were included at multivariable analyses. To assess for bias, we checked for the proportion of listwise deletion when covariates of interest with >10% missingness were included at multivariable analysis. Model selection was based on goodness-of-fit statistics (i.e., adjusted pseudo R², Akaike information criteria, Bayesian information criteria and log-likelihood value). Analysis was done in R software version 4.3.2 (R Foundation for Statistical Computing) and statistical significance was considered at p<0.05.

178 Ethical considerations

- 179 This study was preconceived during the development of clinical and operational guidelines for the
- 180 management of PAC-19 patients in Zambia. The study obtained ethical clearance (waiver for informed
- 181 consent) from the University of Zambia Biomedical Research Ethics Committee (Ref No. 2711-2022),
- approval from the Zambia National Health Research Authority (Ref No: NHRA0002/26/05/2022) and was
- determined to be non-research according to the U.S Centers for Disease Control and Prevention (CDC)
- policy and applicable federal law (See e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C.
- 185 §241(d); 5 U.S.C. 552a; 44 U.S.C.3501 et seq.). CDC investigators did not interact with patients or have
- access to personally identifiable information but participated in protocol development and analysis of
- 187 anonymized data.

188 Results

189 In total, 1,359 patients that attended PAC-19 clinics from August 2020 to January 2023 were in the cross 190 sectional analysis (Fig 1). Of these patients, 548 (40.3%) patients that had ≥2 PAC-19 clinic visits were 191 included in the longitudinal sub-analysis. Most patients (919/1,087, 84.5%) were hospitalized during 192 acute COVID-19 (Table 1). Overall, patients' median age was 53 (IQR: 41-63) years, and 693 (52.9%) were 193 female. Most patients (58.0%) were from Lusaka, where the first two PAC-19 clinics were initially set up. 194 Nearly half of the patients (46.9%) were diagnosed with COVID-19 when delta was the dominant variant 195 (Fig. 2). The median time since COVID-19 diagnosis when patients presented for care in PAC-19 clinics 196 was 4 (IQR:2-6) weeks.



198 Fig 1: Analysis flow diagram of PAC-19 clinic patients in Zambia, August 2020 – January 2023

199

Table 1: Demographic and Clinical Characteristics of Patients who Presented for Care in PAC-19 Clinics in
 Zambia, Aug. 2020–Jan. 2023

	Presence of long COVID symptoms			
Characteristic	Yes (377) n (%)	No (982) n (%)	Overall (1,359) n (%)	p-value [®]
Sex				0.994
Female	197 (53.0)	496 (52.9)	693 (52.9)	
Male	175 (47.0)	441 (47.1)	616 (47.1)	
(Missing)	5	45	50	
Age (years)				0.016
Median (IQR)	53 (43 <i>,</i> 66)	52 (40, 63)	53 (41, 63)	
(Missing)	0	45	45	
Age group (years)				0.039
≤29	22 (5.8)	98 (10.5)	120 (9.1)	
30-39	47 (12.5)	132 (14.1)	179 (13.6)	
40-49	84 (22.3)	188 (20.1)	272 (20.7)	
50-59	82 (21.8)	219 (23.4)	301 (22.9)	
60+	142 (37.7)	300 (32.0)	442 (33.6)	
(Missing)	0	45	45	
PAC-19 Clinic location				0.152
Lusaka city	158 (54.5)	433 (59.4)	591 (58.0)	

	Presence of	of long COVID sympt	oms	
Characteristic	Yes (377) n (%)	No (982) n (%)	Overall (1,359) n (%)	p-value ^a
Other districts	132 (45.5)	296 (40.6)	428 (42.0)	
(Missing)	87	253	340	
Dominant SARS-CoV-2 variant at diagnosis ^b				<0.001
Wild type	17 (4.6)	55 (5.8)	72 (5.4)	
Beta	94 (25.3)	186 (19.5)	280 (21.1)	
Delta	190 (51.1)	433 (45.3)	623 (46.9)	
Omicron	71 (19.1)	282 (29.5)	353 (26.6)	
(Missing)	5	26	31	
Time since COVID-19 diagnosis (weeks) ^c				<0.001
Median (IQR)	6 (5, 10)	3.0 (2, 5)	4.0 (2, 6)	
(Missing)	118	251	369	
Presence of pre-existing comorbidities ^d				<0.001
No	155 (41.1)	550 (56.0)	705 (51.9)	
Yes	222 (58.9)	432 (44.0)	654 (48.1)	
Presence of newly diagnosed medical conditio		132 (1110)	001(10.1)	0.005
No	331 (87.8)	909 (92.6)	1,240 (91.2)	0.000
Yes	46 (12.2)	73 (7.4)	119 (8.8)	
Vaccination status	40 (12.2)	75 (7.4)	115 (0.0)	0.422
Not vaccinated	250 (78.1)	543 (75.8)	793 (76.5)	0.422
Vaccinated	70 (21.9)	173 (24.2)	243 (23.5)	
(Missing)	57	266	323	
Hospitalization status during acute COVID-19	51	200	525	0.428
Outpatient	45 (14.1)	123 (16.0)	168 (15.5)	0.420
Inpatient	274 (85.9)	645 (84.0)	919 (84.5)	
(Missing)	58	214	272	
Hospitalization length of stay (days) ^f	50	214	272	<0.001
1-3	19 (9.4)	139 (26.8)	158 (21.9)	<0.001
1-5 4-7			· · ·	
8-14	38 (18.8)	165 (31.8) 125 (24.1)	203 (28.2)	
≥15	48 (23.8)	125 (24.1)	173 (24.0)	
	97 (48.0)	90 (17.3)	187 (25.9)	
(Missing) Severe COVID ^{f, g}	72	126	198	0.001
	FO (10 2)	102 (20.4)	222 (25 4)	0.001
No	50 (18.2)	183 (28.4)	233 (25.4)	
Yes	224 (81.8)	462 (71.6)	686 (74.6)	
Functional status since COVID-19	444 (55.2)	427 (70.0)		<0.001
Better	144 (55.2)	427 (78.8)	571 (71.1)	
Same/worse ^h	117 (44.8)	115 (21.2)	232 (28.9)	
(Missing)	116	440	556	
Referral to specialist services i	004 (55.3)	a / . =	005 (55.3)	0.001
No	221 (89.1)	614 (95.0)	835 (93.4)	
Yes	27 (10.9)	32 (5.0)	59 (6.6)	
(Missing)	129	336	465	

^a Pearson Chi-square and Kruskal Wallis tests were used for proportions and Wilcoxon rank sum test for medians. Bolded p-values are significant at p<0.05

^b SARS CoV-2 variants classification based on GISAID (2023) rather than sequenced specimens from study patients

^c Computed as a difference in weeks between date of diagnosis and date of presentation at PAC-19 clinic

^d Pre-existing comorbidity: hypertension, diabetes, cardiovascular disease, cancer, immunosuppression, chronic lung, kidney, and liver diseases, obesity, HIV and TB.

^e Comorbidities (hypertension, diabetes, and HIV) diagnosed at the time of SARS CoV-2 infection.


^f Denominator is 919 (i.e., patients hospitalized for acute COVID-19)

^g Acute COVID-19 episode that required supplemental oxygen therapy, intensive care unit stay or treatment with steroids or remdesivir


^h Same or worse limitations in daily activities since acute COVID-19

ⁱ Specialist services included physiotherapy, cardiology, endocrinology, nephrology, psychiatry, and pulmonology









206

At baseline, 654 (48.1%) patients overall, reported having had pre-existing comorbidity. Among these
patients, hypertension (n=465, 71.1%), diabetes (n=172, 26.3%), HIV (n=165, 25.2%) and cardiovascular
disease (n=73, 11.2%) were commonly (frequency of ≥10%) reported (S1 Table). One hundred nineteen
(8.8%) patients had been diagnosed with new medical conditions at the time of SARS-CoV-2 diagnosis.
Of these patients, hypertension and diabetes were detected at SARS-CoV-2 diagnosis in 68 (53.8%) and
64 (53.8%) patients, respectively.

- Among the hospitalized acute COVID-19 patients, the median length of stay was 7 days (IQR:4-15 days).
- 214 Of these inpatients, 686 (74.6%) were categorized as having had severe COVID-19. The medium time
- from the date of COVID-19 diagnosis to when patients presented for care in a PAC-19 clinic was 4 weeks
- 216 (IQR: 2-6 weeks). At first visit to a PAC-19 clinic, 274 (29.8%) hospitalized patients had long COVID.
- Among these long COVID patients, commonly reported symptoms included cough (38.7%), fatigue
- 218 (38.5%), shortness of breath (26.5%), chest pain (20.9%), headache (14.8%), muscles aches/pain (14.1%),
- 219 palpitations (12.5%), joint aches/pain (11.9%), and forgetfulness or brain fog (8.0%). Among the
- outpatients, 103 (23.4%) had long COVID, bringing the overall number of long COVID patients to 377
- 221 (27.7%).

Of all patients, 232 (28.9%) patients had worse or same (limitations in daily activities) functional status

- since acute COVID-19. The functional status patients commonly reported difficulty in undertaking was
- walking long distances greater than 1km (22.6%), day-to-day work/school (cognitive) activities (19.4%),

standing for ≥30 minutes (19.4%), taking care of household tasks (17.8%), and self-care (activities like

bathing and dressing) – 15.1%. Fifty-nine (6.6%) patients were referred to specialist care, including

- 227 cardiology (35.6%), endocrinology (33.9%), psychiatry (25.4%), pulmonology (18.6%), physiotherapy
- 228 (11.0%), and nephrology (1.7%).
- 229 Overall, 243 (23.5%) patients had been vaccinated before being diagnosed with SARS-CoV-2,
- representing 28.5% of patients seen at PAC-19 clinics from April 2021 when COVID-19 vaccines first
- became available in Zambia. Of these vaccinated patients, 102 (42%%) received Johnson and Johnson's
- 232 Janssen (Ad26.COV2.S), 97 (39.9%%) received AstraZeneca (AZD1222), 41 (16.9%%) did not know the
- vaccine type they received, and 3 (1.2%%) received Pfizer-BioNTech (BNT162b2). Fifty-seven (23.4%) had
- received a full series of vaccines >14 days prior to their date of SARS-CoV-2 diagnosis, 31 (12.7%) were
- partially vaccinated (i.e., 2nd dose not yet received), 10 (4.1%) were diagnosed with SARS-CoV-2 within
- 236 14 days of being vaccinations while 148 (60.9%) had missing vaccination dates to be classified.
- Patients with pre-existing comorbidities (adjusted odds ratio [aOR]: 1.50; 95% confidence interval [CI]:
- 1.02-2.21), and with hospital length of stay of 8-14 and ≥15 days were associated with significantly
- 239 higher odds of long COVID (aOR: 1.98; CI: 95% 1.08-3.74, and aOR: 5.37; 95% CI: 2.99-10.0, respectively)
- Table 2. Patients who had severe COVID-19 had 3.23-fold (95% CI: 1.68-6.75) higher odds of presenting
- 241 with long COVID. Independently, vaccinated patients had non-significant reduced likelihood of long
- 242 COVID (OR: 0.94; 95% CI: 0.64-1.36) while those who were referred to specialist services had 1.88-fold
- 243 (95% CI: 1.00-3.48; p-value=0.045) increased likelihood of long COVID.
- Table 2: Factors associated with long COVID at first visit to PAC-19 clinic among patients hospitalized for
 acute COVID-19 in Zambia, August 2020 January 2023 (N=919)

	5 January 2025 (N=515)		
Variable	Unadjusted OR (95% CI)	p-value ^a	Adjusted OR (95% CI)	p-value [*]
Sex				
Female	Referent	-	Referent	-
Male	0.98 (0.74, 1.31)	0.912	0.92 (0.65-1.32)	0.667
Age group (years)				
≤29	Referent	-	Referent	-
30-39	1.73 (0.88, 3.51)	0.116	0.87 (0.38, 2.01)	0.741
40-49	2.01 (1.09, 3.87)	0.029	0.82 (0.39, 1.76)	0.596
50-59	1.69 (0.93, 3.24)	0.096	0.70 (0.33, 1.51)	0.350
60+	1.86 (1.05, 3.47)	0.041	0.61 (0.30, 1.28)	0.181

11

Variable	Unadjusted OR (95% CI)	p-value ^a	Adjusted OR (95% Cl)	p-value
Presence of pre-existing comorbidities ^b				
No	Referent		Referent	-
Yes	1.50 (1.12, 2.01)	0.006	1.50 (1.02, 2.21)	0.041
Presence of newly diagnosed medical conditions ^c				
No	Referent	-	Referent	-
Yes	1.48 (0.94, 2.30)	0.084	1.34 (0.78, 2.28)	0.284
Hospital length of stay (days)				
1-3	Referent	-	Referent	-
4-7	1.68 (0.94, 3.11)	0.086	1.26 (0.68, 2.39)	0.478
8-14	2.81 (1.59, 5.14)	<0.001	1.98 (1.08, 3.74)	0.031
≥15	7.88 (4.60, 14.1)	<0.001	5.37 (2.99, 10.0)	<0.001
Severe COVID-19 ^d				
No	Referent		Referent	-
Yes	1.77 (1.26, 2.54)	0.001	3.22 (1.68, 6.73)	<0.001
Vaccination status ^e				
Not vaccinated	Referent		-	-
Vaccinated	0.94 (0.64, 1.36)	0.737	-	-
Referral to specialist services ^e				
No	Referent		-	-
Yes	1.88 (1.00, 3.48)	0.045	-	-

Abbreviation: OR - odds ratio; CI - confidence interval

^a Bolded p-values are significant at p<0.05

^b Pre-existing comorbidity: hypertension, diabetes, cardiovascular disease, cancer, immunosuppression, chronic lung, kidney, and liver diseases, obesity, HIV and TB.

^c Comorbidities (hypertension, diabetes, and HIV) diagnosed at the time of SARS CoV-2 infection.

^d Acute COVID-19 episode that required supplemental oxygen therapy, intensive care unit stay or treatment with steroids/ remdesivir

^e Vaccination status and referral to specialist services were not adjusted for at multivariable analysis due to >10% missingness which resulted in 50.5% listwise deletion.

246

247 In the additional cross-sectional analysis that included both inpatients and outpatients during acute

248 COVID-19 (S2 Table), inpatients were associated with non-significant increased odds of long COVID (aOR:

1.05; 95% CI: 0.72-1.55). Patients with the presence of comorbidities were, however, associated with

significantly higher odds of long COVID (aOR: 1.55; 95% CI: 1.16-2.08) while the presence of newly

diagnosed medical conditions had a non-significant increase likelihood of long COVID. Patients aged 40-

49 years were significantly associated with 1.79-fold increased likelihood of long COVID (95% CI: 1.03-

253 3.22). Independently, patients referred to specialist services were 2.34 times (95% CI: 1.37-4.00) more

likely to present with long COVID. Males compared to females and having been vaccinated against

255 COVID-19 were associated with non-significant reduced odds of long COVID.

In the longitudinal analysis (S1 Fig), the overall median time patients presented at a PAC-19 clinic was 7

257 (IQR: 4-12) weeks. Longitudinally (Fig 3), the most frequently (≥5% at any PAC-19 clinic visit) reported

258 long COVID symptoms were cough (16.9%), fatigue (16.4%), shortness of breath (10.6%), chest pain 259 (8.4%), headache (8.3%), palpitations (6.6%) and muscle aches/pains (5.2%), and forgetfulness (3.0%). 260 The prevalence of long COVID significantly declined (p<0.001) from 75.4% at the first PAC-19 clinic visit 261 to 53.5% at the second visit, 59.8% at the third visit, 49.6% at the fourth visit, and 26.0% at the final visit 262 (S3 Table). Overall, the proportion of vaccinated patients attending PAC-19 clinics increased from 20% at 263 the first visit to 58% at the fifth visit; an increase that will statistically significant (p<0.001). Similarly, 264 comparatively significantly (p=0.002) larger proportion of patients with comorbidities presented in 265 subsequent PAC-19 clinic visits than at the first visit. The proportion of patients with newly diagnosed 266 medical conditions longitudinally declined; this was, however, non-significant (p=0.953).



Fig 3: Longitudinal frequency of most common long COVID symptoms by PAC-19 clinic visit, Aug. 2020 Jan. 2023

270

271 We found similar associations with long COVID in the longitudinal analysis (Table 3) as with the cross-272 sectional analysis (Table 2). Across subsequent clinical visits, the odds of long COVID declined overall. 273 Patients with hospital length of stay of ≥15 days and those with severe COVID-19 had significantly 274 increased likelihood of presenting with long COVID (aOR: 4.30; 95% CI: 1.54-12.0, and aOR: 1.89; 95% CI: 275 1.02-3.49, respectively). Longitudinally, vaccinated patients had a non-significant reduced odds of long 276 COVID (aOR: 0.78; 95% CI: 0.45-1.35). Similarly, sex, age, presence of comorbidities and newly diagnosed 277 medical conditions were associated with non-significant likelihood of long COVID. For the longitudinal 278 model, the conditional ICC was estimated to be 0.562; suggesting that 56.2% of the longitudinal variance 279 in long COVID was attributable to between patient differences.

- 280
- 281

282
283

Table 3: Factors longitudinally association with long COVID among acute COVID-19 hospitalized patients inZambia, August 2020 – January 2023 (N=540)

Veriekle	Adjusted model ^a		Fully adjusted model ^b	
Variable	aOR (95% CI)	p-value ^c	aOR (95% CI)	p-value ^c
PAC-19 clinic visit				
1	Referent	-	Referent	-
2	0.18 (0.12, 0.27)	<0.001	0.18 (0.11, 0.31)	<0.001
3	0.09 (0.04, 0.18)	<0.001	0.09 (0.04, 0.21)	<0.001
4	0.02 (0.01, 0.06)	<0.001	0.02 (0.01, 0.06)	<0.001
5	0.00 (0.00, 0.01)	<0.001	0.00 (0.00, 0.02)	<0.001
Sex				
Female	Referent	-	Referent	-
Male	0.81 (0.52, 1.27)	0.367	0.75 (0.42, 1.36)	0.348
Age group (years)				
≤29	Referent	-	Referent	-
30-39	2.25 (0.64 , 7.94)	0.208	1.07 (0.19, 6.09)	0.937
40-49	1.60 (0.51, 5.02)	0.422	0.68 (0.14, 3.26)	0.634
50-59	1.56 (0.51, 4.81)	0.438	0.79 (0.17, 3.75)	0.765
60+	2.56 (0.85 , 7.67)	0.094	1.27 (0.27, 5.84)	0.762
Presence of newly diagnosed medical cond	litions			
No	Referent	-	Referent	-
Yes	1.55 (0.76, 3.14)	0.227	1.41 (0.58, 3.43)	0.449
Presence of comorbidities				
No	Referent	-	Referent	-
Yes	1.86 (1.18, 2.92)	0.007	1.66 (0.88, 3.14)	0.117
Hospital length of stay (days)				
1-3	Referent	-	Referent	-
4-7	1.95 (0.72 , 5.25)	0.187	1.73 (0.65, 4.61)	0.271
8-14	2.18 (0.80 , 5.90)	0.127	1.74 (0.64, 4.71)	0.277
≥15	5.92 (2.14 , 16.42)	0.001	4.30 (1.54, 12.0)	0.005
Severe COVID-19 ^d				
No	Referent	-	Referent	-
Yes	1.44 (0.90, 2.31)	0.124	1.89 (1.02, 3.49)	0.042
Vaccination status				
Not vaccinated	Referent	-	Referent	-
Vaccinated	0.79 (0.50, 1.26)	0.326	0.78 (0.45, 1.35)	0.380
Referral to specialist Services ^e				
No	Referent	-	-	-
Yes	1.01 (0.53, 1.95)	0.973	-	-
Random Effects	- (,,,			
Between PAC-19 clinic visit variance			3.29	
Within PAC-19 clinic visit variance			4.22	
Conditional intraclass correlation			0.56	

^a Models adjusted for fixed effects term PAC-19 clinic visit occasion.

^b Fully adjusted model included measurement occasion fixed effects term (PAC-19 clinic visit occasions) and patient level fixed effects terms: age (<29, 30-39, 40-49, 50-59, or +60 years), presence of comorbidities (yes or no), presence of newly diagnosed comorbidity (yes or no),

Variable	Adjusted m	odel ª	Fully adjusted m	odel ^b
variable	aOR (95% CI)	p-value ^c	aOR (95% CI)	p-value ^c
agute COVID 10 becatelization length of stay (1.2, 4.7	Q 14 and >1E days) says		a soute COVID 10 luss or no) and

acute COVID-19 hospitalization length of stay (1-3, 4-7, 8-14, and ≥15 days), severe COVID-19 during acute COVID-19 (yes or no), and COVID-19 vaccination status (not vaccinated or vaccinated). The random-effects term for longitudinal clustering of repeated measure was the patient.

 $^{\rm c}\,$ Bolded p-values are significant at p<0.05

^d Acute COVID-19 episode that required supplemental oxygen therapy, intensive care unit stay or treatment with steroids/remdesivir ^e Referral to specialist services not adjusted for at multivariable analysis due to 32.6% missingness which resulted in 57.9% listwise deletion.

284

285 In the longitudinal sub-analysis that included both those that were inpatients and outpatients during 286 acute COVID-19 (S4 Table), similar associations were observed as to the cross section sub-analysis (S2 287 Table). The likelihood of presenting with long COVID significantly (p<0.001) declined, overall, across 288 subsequent PAC-19 clinic visits (S4 Table). The presence of comorbidities were longitudinally associated 289 with increased odds of long COVID by a factor of 1.67 (95% CI: 1.02-2.75). Hospitalized patients during 290 acute COVID-19, vaccinated and male patients were associated with non-significant reduced likelihood 291 of long COVID. Similarly, order age groups and presence of newly diagnosed medical conditions were 292 associated with non-significant, however increased, odds of long COVID.

293 Discussion

294 Long COVID symptoms were common among patients presenting for care in specialized post-acute

295 COVID-19 clinics in Zambia, which could represent potential substantial morbidity from COVID-19.

296 Factors associated with long COVID in Zambia included severe COVID-19, hospital length of stay and

297 presence of pre-existing comorbidities. Hospitalization was not significantly associated with long COVID

while patients with limitations in daily activities that may have impacted on the patients' functional

status were independently associated with long COVID. Longitudinally vaccination patients had

300 indistinguishable likelihood of long COVID and so was sex and age.

A severe form of COVID-19 is known to increase the risk of an intense immune response that could lead to widespread inflammation [50]. The inflammatory response can persist post-acute infection and could have led to the immune system being dysregulated, leading to prolonged persistent symptoms and complications of COVID-19 in the patients. This could have led to observed association of severe COVID-19 long COVID as has been reported in other studies [35, 36, 51, 52].

306 Patients with longer hospital stays may have received intensive medical interventions and additional

307 treatments. This could have potentially affected the immune response and the body's ability to recover

308 from the acute COVID-19p, which in turn may have increased the likelihood of long COVID. Furthermore,

patients with pre-existing comorbidities may have been more susceptible to severe COVID-19 and may
have been at higher risk of developing long COVID. This is consistent with what is reported by other
studies on patients with longer hospitalization stay for acute COVID-19 or pre-existing comorbidities and
their association to long COVID [52-54].

Patients referred to specialist services may have had residual organ damage from acute COVID-19 which may have required specialist care. This may have been closely related to the observed limitations in daily activities that may have impacted on the patients' functional status since acute COVID-19 as have been reported in a previous study [9]. Although this association was independently significant, we could not adjust for it at multivariable analysis due to missingness that resulted in listwise deletion of more than half the study sample. Furthermore, no feedback systems were in place to inform PAC-19 clinics of the outcome of specialist care of referred patients.

320 COVID-19 vaccines have been shown to be effective at preventing symptomatic SARS-CoV-2 infections 321 and long COVID [55, 56]. In this study, however, vaccinated patients failed to show significant protective 322 association between COVID vaccination and long COVID. A possible explanation for this finding might be 323 the heterogeneity in vaccination status during the study since Zambia only began offering COVID-19 324 vaccination in April 2021 (i.e., right before the delta wave and ~8 months after patients began 325 presenting for care in PAC-19 clinics) [57]. For example, among the patients diagnosed with SARS-CoV-2 326 during the wild type and beta dominant variants periods, prior to publicly available COVID-19 327 vaccination in Zambia, only 1 patient ever reported being vaccinated. 328 Unlike pre-existing comorbidities, newly diagnosed medical conditions had a non-significant association

with long COVID. Newly diagnosed medical conditions in COVID-19 patients may have been as a result of
 multiorgan effects or autoimmune conditions [3]. Fewer patients, overall, had newly diagnosed medical
 conditions which could explain the non-significant association. Sex and age were similarly not

associated with long COVID which seem to suggest that factors associated with long COVID in Zambiawere largely clinical as opposed to demographic.

With regards to recovery time from long COVID, most patients with long COVID had symptom resolution by the second month of follow up. Overall, we found that commonly reported long COVID symptoms in Zambia were similar to findings in other studies [35, 36, 38, 52]. However, symptoms like forgetfulness (commonly reported among long COVID patients) and change in sleep were less commonly reported in our study compared to previous reports [17, 20]. 339 In both the cross-sectional and longitudinal analysis, inpatients compared to outpatient care during 340 COVID-19 episode were found to be associated with indistinguishable likelihood of long COVID. One 341 reason for this might be that those who were outpatient and attending PAC-19 clinics were a special 342 subset of outpatients with COVID-19 (i.e., they were seeking out or were referred for follow-up care 343 during acute COVID-19e). Furthermore, inpatients (the majority of whom had severe COVID-19) might 344 have been more likely to be referred to PAC-19 clinic whereas those who were outpatient were likely 345 self-referral to PAC-19 clinic meaning only those who really needed it (i.e., those with ongoing 346 symptoms) were in this study.

The findings in this study are subject to several limitations. Firstly, only patients attending PAC-19 clinics were included in the study, so other patients with long COVID who sought care elsewhere (or didn't seek care) were not included. This potentially represents some form of selection bias within the study since other long COVID patients could have by-passed the PAC-19 clinic and presented directly to clinicians or specialist service at outpatient departments. Furthermore, PAC-19 clinics took time to scale-up throughout Zambia and some persons might still have faced difficulty accessing them. Overall, fewer than 1% of the over 344,000 confirmed COVID-19 cases in Zambia as of January 2023 presented for care

in PAC-19 clinics.

Secondly, COVID-19 illness history (i.e., date of SARS-CoV-2 testing, hospitalization status, vaccination history, acute COVID-19 episode details, etc.) were self-reported by patients to clinicians which cannot rule out self-serving bias. Thirdly, the study utilized routinely collected clinical information from PAC-19 clinics which had substantial missingness for some key variables such as vaccination status and referral to specialist services. Thus, these variables were not adjusted for at multivariable analyses so as to maintain sample size. And lastly, patients were not retested for SAR-CoV-2 infection at subsequent PAC-19 review visits and so the possibility of reinfection could not be ruled out.

362 Conclusion

Given the burden of COVID-19 in Zambia, the findings of a potentially substantial morbidity due to long COVID, and that yet few patients overall with COVID-19 had attended a PAC-19 clinic, scaling up PAC-19 care services and integrating into routine clinical care could improve access by patients and further aid in understanding the true burden of long COVID in Zambia. This could be coupled with efforts to expand knowledge of long COVD among clinicians and the general population in Zambia. Scaling of vaccination, may likely, provide better outcomes not only for long COVID but also during acute SARS-CoV-2 infection. Improving data quality for routine clinical data, could possibly be achieved by utilizing the existing

- 370 electronic health record in Zambia (SmartCare) for all clinical encounters. Information sharing between
- 371 referral care services and PAC-19 clinics could aid in understanding the outcome of long COVID among
- 372 patients requiring specialist care.
- 373 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not necessarily
- 374 represent the official position of the US Centers for Disease Control and Prevention (CDC) or the study
- 375 funders.

376 Supporting information

Histogram of longitudinal PAC-19 clinic attendance (all visits) by time since COVID-19 S1 Fig: 377 diagnosis, August 2020 January 2023 378 379 380 S1 Table: Frequencies of pre-existing and newly diagnosed comorbidities of PAC-19 Clinic Patients 381 in Zambia, Aug. 2020–Jan. 2023 382 383 S2 Table: Factors associated with long COVID at first visit to PAC-19 clinic among acute COVID-19 384 inpatients and outpatients in Zambia, August 2020 – January 2023 (N=1,359) 385 S3 Table: Longitudinal Demographic and Clinical Characteristics of PAC-19 Clinic Patients in 386 387 Zambia, Aug. 2020–Jan. 2023 388 389 S4 Table: Longitudinal risk factors and association for long COVID among acute COVID-19 hospitalized and non-hospitalized patients in Zambia, August 2020 – January 2023 390 391 (N=548) 392

393

394 References

- 395 1. WHO. International Health Regulations Emergency Committee on novel coronavirus in China. 396 2020 [cited 2022 12 May]; Available from: https://www.who.int/newsroom/events/detail/2020/01/30/default-calendar/international-health-regulations-emergency-397 398 committee-on-novel-coronavirus-in-china. 399 2. WHO. WHO Coronavirus (COVID-19) Dashboard. 2023 [cited 2022 16 October]; Available from: 400 https://covid19.who.int/. Raveendran, A.V., R. Jayadevan, and S. Sashidharan, Long COVID: An overview. Diabetes Metab 401 3. 402 Syndr, 2021. 15(3): p. 869-875. 403 4. Klok, F.A., et al., The Post-COVID-19 Functional Status scale: a tool to measure functional status
- 404 *over time after COVID-19.* European Respiratory Journal, 2020. **56**(1): p. 2001494.

405	5.	Peghin, M., et al., Post-COVID-19 symptoms 6 months after acute infection among hospitalized
406		and non-hospitalized patients. Clin Microbiol Infect, 2021. 27(10): p. 1507-1513.
407	6.	Soriano, J.B., et al., A clinical case definition of post-COVID-19 condition by a Delphi consensus.
408	_	Lancet Infect Dis, 2022. 22(4): p. e102-e107.
409	7.	Venturelli, S., et al., Surviving COVID-19 in Bergamo province: a post-acute outpatient re-
410		evaluation. Epidemiology and Infections, 2021. 149: p. e32.
411	8.	Ahmed, H., et al., Long-term clinical outcomes in survivors of severe acute respiratory syndrome
412		and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU
413		admission: A systematic review and meta-analysis. Journal of Rehabil itation of Medicine, 2020.
414	0	52 (5): p. jrm00063.
415	9.	Hui, D.S., et al., Impact of severe acute respiratory syndrome (SARS) on pulmonary function,
416	10	functional capacity and quality of life in a cohort of survivors. Thorax, 2005. 60 (5): p. 401-9.
417	10.	Lam, M.H., et al., <i>Mental morbidities and chronic fatigue in severe acute respiratory syndrome</i>
418	11	survivors: long-term follow-up. JAMA Internal Medicine, 2009. 169 (22): p. 2142-7.
419 420	11.	Lee, S.H., et al., Depression as a Mediator of Chronic Fatigue and Post-Traumatic Stress
420 421		Symptoms in Middle East Respiratory Syndrome Survivors. Psychiatry Investigation, 2019. 16 (1):
421	12.	p. 59-64. Thaweethai, T., et al., <i>Development of a Definition of Postacute Sequelae of SARS-CoV-2</i>
422	12.	Infection. JAMA, 2023. 329 (22): p. 1934-1946.
424	13.	Vahey, G.M., et al., Symptom Profiles and Progression in Hospitalized and Nonhospitalized
425	15.	Patients with Coronavirus Disease, Colorado, USA, 2020. Emerg Infect Dis, 2021. 27 (2): p. 385-
426		395.
427	14.	Nalbandian, A., et al., <i>Post-acute COVID-19 syndrome</i> . Nature Medicine, 2021. 27 (4): p. 601-615.
428	15.	Chippa, V., A. Aleem, and F. Anjum, <i>Post Acute Coronavirus (COVID-19) Syndrome</i> . 2021:
429		StatPearls Publishing, Treasure Island (FL).
430	16.	Danesh, V., et al., Symptom Clusters Seen in Adult COVID-19 Recovery Clinic Care Seekers. J Gen
431		Intern Med, 2023. 38 (2): p. 442-449.
432	17.	Davis, H.E., et al., Characterizing long COVID in an international cohort: 7 months of symptoms
433		and their impact. EClinicalMedicine, 2021. 38: p. 101019.
434	18.	WHO. Post COVID-19 condition (Long COVID). 2022 [cited 2023 6 July]; Available from:
435		https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition.
436	19.	Carfi, A., R. Bernabei, and F. Landi, Persistent Symptoms in Patients After Acute COVID-19. JAMA,
437		2020. 324 (6): p. 603-605.
438	20.	Huang, C., et al., 6-month consequences of COVID-19 in patients discharged from hospital: a
439		<i>cohort study.</i> Lancet, 2021. 397 (10270): p. 220-232.
440	21.	Tenforde, M.W., et al., Symptom Duration and Risk Factors for Delayed Return to Usual Health
441		Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States,
442		<i>March-June 2020</i> . MMWR Morb Mortal Wkly Rep, 2020. 69 (30): p. 993-998.
443	22.	Ballering, A.V., et al., Persistence of somatic symptoms after COVID-19 in the Netherlands: an
444		observational cohort study. Lancet, 2022. 400 (10350): p. 452-461.
445	23.	Ayoubkhani, D., et al., Risk of Long COVID in People Infected With Severe Acute Respiratory
446		Syndrome Coronavirus 2 After 2 Doses of a Coronavirus Disease 2019 Vaccine: Community-
447		Based, Matched Cohort Study. Open Forum Infect Dis, 2022. 9 (9): p. ofac464.
448	24.	Bull-Otterson, L., et al., Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64
449		and ≥65 Years — United States, March 2020–November 2021. MMWR Morb Mortal Wkly Rep,
450		2022. 71 (21): p. 713-7.
451	25.	Ceban, F., et al., Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic
452		<i>review and meta-analysis.</i> Brain Behav Immun, 2022. 101 : p. 93-135.

 Davis, H.E., et al., Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology, 2023. Nyasulu, P.S., J.L. Tamuzi, and R.T. Erasmus, Burden, causation, and particularities of Long COVID in African populations: A rapid systematic review. UID Regions, 2023. 8: p. 137-144. Antonelli, M., et al., Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case- control study. Lancet Infect Dis, 2022. 22(1): p. 43-55. Morello, R., et al., Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study. eClinicalMedicine, 2023. 59: p. 101961. Tsampasian, V., et al., Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis. JAMA Internal Medicine, 2023. 183(6): p. 566-580. Frallonardo, L., et al., Incidence and burden of long COVID in Africa: a systematic review and meta-analysis. Scientific Reports, 2023. 13(1): p. 21482. Osikomaiya, B., et al., Tong COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infectious Diseases, 2021. 21(1): p. 304. Müller, S.A., et al., Prevalence and risk factors for long COVID and post-COVID-19 condition in Africa: a systematic review. Lancet Glob Health, 2023. 11(11): p. e1713-e1724. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect Dis, 2021. 21(1): p. 304. Dryden, M., et al., Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. Lancet Glob Health, 2022. 10(9): p. e1247-e1256. Moyo, E., et al., Risk factors and clinical presentations of long COVID in Africa: A scoping review. Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 	453 454	26.	Xu, E., Y. Xie, and Z. Al-Aly, <i>Long-term neurologic outcomes of COVID-19</i> . Nat Med, 2022. 28 (11): p. 2406-2415.
 Reviews Microbiology, 2023. Nyasulu, P.S., J.L. Tamuzi, and R.T. Erasmus, Burden, causation, and particularities of Long COVII in African populations: A rapid systematic review. IJID Regions, 2023. 8: p. 137-144. 29. Antonelli, M., et al., Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case- control study. Lancet Infect Dis, 2022. 22(1): p. 43-55. 30. Morello, R., et al., Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study. eClinicalMedicine, 2023. 59: p. 101961. 31. Tsampasian, V., et al., Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis. JAMA Internal Medicine, 2023. 183(6): p. 566-580. 32. Frallonardo, L., et al., Incidence and burden of long COVID in Africa: a systematic review and meta-analysis. Scientific Reports, 2023. 13(1): p. 21482. 33. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infectious Diseases, 2021. 21(1): p. 304. 34. Müller, S.A., et al., Prevalence and risk factors for long COVID and post-COVID-19 condition in Africa: a systematic review. Lancet Glob Health, 2023. 11(11): p. e1713-e1724. 35. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect Dis, 2021. 21(1): p. 304. 36. Dryden, M., et al., Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. Lancet Glob Health, 2022. 10(9): p. e1247-e1256. 37. Moyo, E., et al., Risk factors and clinical presentations of long COVID in Africa: A scoping review. 477 Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 		27.	•
 in African populations: A rapid systematic review. IJID Regions, 2023. 8: p. 137-144. 29. Antonelli, M., et al., <i>Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study</i>. Lancet Infect Dis, 2022. 22(1): p. 43-55. 30. Morello, R., et al., <i>Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study</i>. eClinicalMedicine, 2023. 59: p. 101961. 31. Tsampasian, V., et al., <i>Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis</i>. JAMA Internal Medicine, 2023. 183(6): p. 566-580. 32. Frallonardo, L., et al., <i>Incidence and burden of long COVID in Africa: a systematic review and meta-analysis</i>. Scientific Reports, 2023. 13(1): p. 21482. 33. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria</i>. BMC Infectious Diseases, 2021. 21(1): p. 304. 34. Müller, S.A., et al., <i>Prevalence and risk factors for long COVID and post-COVID-19 condition in Africa: a systematic review</i>. Lancet Glob Health, 2023. 11(11): p. e1713-e1724. 35. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria</i>. BMC Infect Dis, 2021. 21(1): p. 304. 36. Dryden, M., et al., <i>Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study</i>. Lancet Glob Health, 2022. 10(9): p. e1247-e1256. 37. Moyo, E., et al., <i>Risk factors and clinical presentations of long COVID in Africa: A scoping review</i>. 474 36. Dryden, M., et al., <i>Risk factors and clinical presentations of long COVID in Africa: A scoping review</i>. 476 37. Moyo, E., et al., <i>Risk factors and clinical presentations of long COVID in Africa: A scoping review</i>. 			
 Antonelli, M., et al., <i>Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in</i> <i>UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-</i> <i>control study</i>. Lancet Infect Dis, 2022. 22(1): p. 43-55. Morello, R., et al., <i>Risk factors for post-COVID-19 condition (Long Covid) in children: a</i> <i>prospective cohort study</i>. eClinicalMedicine, 2023. 59: p. 101961. Tsampasian, V., et al., <i>Risk Factors Associated With Post-COVID-19 Condition: A Systematic</i> <i>Review and Meta-analysis</i>. JAMA Internal Medicine, 2023. 183(6): p. 566-580. Frallonardo, L., et al., <i>Incidence and burden of long COVID in Africa: a systematic review and</i> <i>meta-analysis</i>. Scientific Reports, 2023. 13(1): p. 21482. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in</i> <i>Lagos State, Nigeria</i>. BMC Infectious Diseases, 2021. 21(1): p. 304. Müller, S.A., et al., <i>Prevalence and risk factors for long COVID and post-COVID-19 condition in</i> <i>Africa: a systematic review</i>. Lancet Glob Health, 2023. 11(11): p. e1713-e1724. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in</i> <i>Lagos State, Nigeria</i>. BMC Infect Dis, 2021. 21(1): p. 304. Dryden, M., et al., <i>Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in</i> <i>South Africa: a prospective cohort study</i>. Lancet Glob Health, 2022. 10(9): p. e1247-e1256. Moyo, E., et al., <i>Risk factors and clinical presentations of long COVID in Africa: A scoping review</i>. Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 	457	28.	Nyasulu, P.S., J.L. Tamuzi, and R.T. Erasmus, Burden, causation, and particularities of Long COVID
 UK users of the COVID Symptom Study app: a prospective, community-based, nested, case- control study. Lancet Infect Dis, 2022. 22(1): p. 43-55. 30. Morello, R., et al., <i>Risk factors for post-COVID-19 condition (Long Covid) in children: a</i> prospective cohort study. eClinicalMedicine, 2023. 59: p. 101961. 31. Tsampasian, V., et al., <i>Risk Factors Associated With Post-COVID-19 Condition: A Systematic</i> <i>Review and Meta-analysis.</i> JAMA Internal Medicine, 2023. 183(6): p. 566-580. 32. Frallonardo, L., et al., <i>Incidence and burden of long COVID in Africa: a systematic review and</i> <i>meta-analysis.</i> Scientific Reports, 2023. 13(1): p. 21482. 33. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in</i> <i>Lagos State, Nigeria.</i> BMC Infectious Diseases, 2021. 21(1): p. 304. 34. Müller, S.A., et al., <i>Prevalence and risk factors for long COVID and post-COVID-19 condition in</i> <i>Africa: a systematic review.</i> Lancet Glob Health, 2023. 11(11): p. e1713-e1724. 35. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in</i> <i>Lagos State, Nigeria.</i> BMC Infect Dis, 2021. 21(1): p. 304. 36. Dryden, M., et al., <i>Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in</i> <i>South Africa: a prospective cohort study.</i> Lancet Glob Health, 2022. 10(9): p. e1247-e1256. 37. Moyo, E., et al., <i>Risk factors and clinical presentations of long COVID in Africa: A scoping review.</i> Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 	458		in African populations: A rapid systematic review. IJID Regions, 2023. 8: p. 137-144.
 461 control study. Lancet Infect Dis, 2022. 22(1): p. 43-55. 462 30. Morello, R., et al., <i>Risk factors for post-COVID-19 condition (Long Covid) in children: a</i> 463 prospective cohort study. eClinicalMedicine, 2023. 59: p. 101961. 464 31. Tsampasian, V., et al., <i>Risk Factors Associated With Post-COVID-19 Condition: A Systematic</i> 465 <i>Review and Meta-analysis.</i> JAMA Internal Medicine, 2023. 183(6): p. 566-580. 466 32. Frallonardo, L., et al., <i>Incidence and burden of long COVID in Africa: a systematic review and</i> 467 <i>meta-analysis.</i> Scientific Reports, 2023. 13(1): p. 21482. 468 33. Osikomaiya, B., et al., <i>Icong COVID': persistent COVID-19 symptoms in survivors managed in</i> 469 <i>Lagos State, Nigeria.</i> BMC Infectious Diseases, 2021. 21(1): p. 304. 470 34. Müller, S.A., et al., <i>Prevalence and risk factors for long COVID and post-COVID-19 condition in</i> 471 <i>Africa: a systematic review.</i> Lancet Glob Health, 2023. 11(11): p. e1713-e1724. 472 35. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in</i> 473 <i>Lagos State, Nigeria.</i> BMC Infect Dis, 2021. 21(1): p. 304. 474 36. Dryden, M., et al., <i>Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in</i> 475 <i>South Africa: a prospective cohort study.</i> Lancet Glob Health, 2022. 10(9): p. e1247-e1256. 476 37. Moyo, E., et al., <i>Risk factors and clinical presentations of long COVID in Africa: A scoping review.</i> 477 Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 	459	29.	Antonelli, M., et al., Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in
 Morello, R., et al., <i>Risk factors for post-COVID-19 condition (Long Covid) in children: a</i> <i>prospective cohort study.</i> eClinicalMedicine, 2023. 59: p. 101961. Tsampasian, V., et al., <i>Risk Factors Associated With Post-COVID-19 Condition: A Systematic</i> <i>Review and Meta-analysis.</i> JAMA Internal Medicine, 2023. 183(6): p. 566-580. Frallonardo, L., et al., <i>Incidence and burden of long COVID in Africa: a systematic review and</i> <i>meta-analysis.</i> Scientific Reports, 2023. 13(1): p. 21482. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in</i> <i>Lagos State, Nigeria.</i> BMC Infectious Diseases, 2021. 21(1): p. 304. Müller, S.A., et al., <i>Prevalence and risk factors for long COVID and post-COVID-19 condition in</i> <i>Africa: a systematic review.</i> Lancet Glob Health, 2023. 11(11): p. e1713-e1724. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in</i> <i>Lagos State, Nigeria.</i> BMC Infect Dis, 2021. 21(1): p. 304. Müller, S.A., et al., <i>Prevalence and risk factors for long COVID and post-COVID-19 condition in</i> <i>Africa: a systematic review.</i> Lancet Glob Health, 2023. 11(11): p. e1713-e1724. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in</i> <i>Lagos State, Nigeria.</i> BMC Infect Dis, 2021. 21(1): p. 304. Dryden, M., et al., <i>Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in</i> <i>South Africa: a prospective cohort study.</i> Lancet Glob Health, 2022. 10(9): p. e1247-e1256. Moyo, E., et al., <i>Risk factors and clinical presentations of long COVID in Africa: A scoping review.</i> Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 	460		UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-
 463 prospective cohort study. eClinicalMedicine, 2023. 59: p. 101961. 464 31. Tsampasian, V., et al., Risk Factors Associated With Post-COVID-19 Condition: A Systematic 465 Review and Meta-analysis. JAMA Internal Medicine, 2023. 183(6): p. 566-580. 466 32. Frallonardo, L., et al., Incidence and burden of long COVID in Africa: a systematic review and 467 meta-analysis. Scientific Reports, 2023. 13(1): p. 21482. 468 33. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in 469 Lagos State, Nigeria. BMC Infectious Diseases, 2021. 21(1): p. 304. 470 34. Müller, S.A., et al., Prevalence and risk factors for long COVID and post-COVID-19 condition in 471 Africa: a systematic review. Lancet Glob Health, 2023. 11(11): p. e1713-e1724. 472 35. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in 473 Lagos State, Nigeria. BMC Infect Dis, 2021. 21(1): p. 304. 474 36. Dryden, M., et al., Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in 475 South Africa: a prospective cohort study. Lancet Glob Health, 2022. 10(9): p. e1247-e1256. 476 37. Moyo, E., et al., Risk factors and clinical presentations of long COVID in Africa: A scoping review. 477 Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 	461		, , , , , , , , , , , , , , , , , , , ,
 Tsampasian, V., et al., <i>Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis.</i> JAMA Internal Medicine, 2023. 183(6): p. 566-580. Frallonardo, L., et al., <i>Incidence and burden of long COVID in Africa: a systematic review and meta-analysis.</i> Scientific Reports, 2023. 13(1): p. 21482. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria.</i> BMC Infectious Diseases, 2021. 21(1): p. 304. Müller, S.A., et al., <i>Prevalence and risk factors for long COVID and post-COVID-19 condition in Africa: a systematic review.</i> Lancet Glob Health, 2023. 11(11): p. e1713-e1724. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria.</i> BMC Infect Dis, 2021. 21(1): p. 304. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria.</i> BMC Infect Dis, 2021. 21(1): p. 304. Dryden, M., et al., <i>Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study.</i> Lancet Glob Health, 2022. 10(9): p. e1247-e1256. Moyo, E., et al., <i>Risk factors and clinical presentations of long COVID in Africa: A scoping review.</i> Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 		30.	
 Review and Meta-analysis. JAMA Internal Medicine, 2023. 183(6): p. 566-580. Frallonardo, L., et al., Incidence and burden of long COVID in Africa: a systematic review and meta-analysis. Scientific Reports, 2023. 13(1): p. 21482. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infectious Diseases, 2021. 21(1): p. 304. Müller, S.A., et al., Prevalence and risk factors for long COVID and post-COVID-19 condition in Africa: a systematic review. Lancet Glob Health, 2023. 11(11): p. e1713-e1724. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in Africa: a systematic review. Lancet Glob Health, 2023. 11(11): p. e1713-e1724. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect Dis, 2021. 21(1): p. 304. Dryden, M., et al., Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. Lancet Glob Health, 2022. 10(9): p. e1247-e1256. Moyo, E., et al., Risk factors and clinical presentations of long COVID in Africa: A scoping review. Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 			
 Frallonardo, L., et al., <i>Incidence and burden of long COVID in Africa: a systematic review and</i> <i>meta-analysis.</i> Scientific Reports, 2023. 13(1): p. 21482. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in</i> <i>Lagos State, Nigeria.</i> BMC Infectious Diseases, 2021. 21(1): p. 304. Müller, S.A., et al., <i>Prevalence and risk factors for long COVID and post-COVID-19 condition in</i> <i>Africa: a systematic review.</i> Lancet Glob Health, 2023. 11(11): p. e1713-e1724. Osikomaiya, B., et al., <i>'Long COVID': persistent COVID-19 symptoms in survivors managed in</i> <i>Lagos State, Nigeria.</i> BMC Infect Dis, 2021. 21(1): p. 304. Dryden, M., et al., <i>Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in</i> <i>South Africa: a prospective cohort study.</i> Lancet Glob Health, 2022. 10(9): p. e1247-e1256. Moyo, E., et al., <i>Risk factors and clinical presentations of long COVID in Africa: A scoping review.</i> Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 		31.	
 467 meta-analysis. Scientific Reports, 2023. 13(1): p. 21482. 468 33. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in 469 Lagos State, Nigeria. BMC Infectious Diseases, 2021. 21(1): p. 304. 470 34. Müller, S.A., et al., Prevalence and risk factors for long COVID and post-COVID-19 condition in 471 Africa: a systematic review. Lancet Glob Health, 2023. 11(11): p. e1713-e1724. 472 35. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in 473 Lagos State, Nigeria. BMC Infect Dis, 2021. 21(1): p. 304. 474 36. Dryden, M., et al., Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in 475 South Africa: a prospective cohort study. Lancet Glob Health, 2022. 10(9): p. e1247-e1256. 476 37. Moyo, E., et al., Risk factors and clinical presentations of long COVID in Africa: A scoping review. 477 Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 			
 33. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infectious Diseases, 2021. 21(1): p. 304. 34. Müller, S.A., et al., Prevalence and risk factors for long COVID and post-COVID-19 condition in Africa: a systematic review. Lancet Glob Health, 2023. 11(11): p. e1713-e1724. 35. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect Dis, 2021. 21(1): p. 304. 36. Dryden, M., et al., Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. Lancet Glob Health, 2022. 10(9): p. e1247-e1256. 37. Moyo, E., et al., Risk factors and clinical presentations of long COVID in Africa: A scoping review. Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 		32.	
 Lagos State, Nigeria. BMC Infectious Diseases, 2021. 21(1): p. 304. Müller, S.A., et al., Prevalence and risk factors for long COVID and post-COVID-19 condition in Africa: a systematic review. Lancet Glob Health, 2023. 11(11): p. e1713-e1724. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect Dis, 2021. 21(1): p. 304. Dryden, M., et al., Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. Lancet Glob Health, 2022. 10(9): p. e1247-e1256. Moyo, E., et al., Risk factors and clinical presentations of long COVID in Africa: A scoping review. Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 			
 470 34. Müller, S.A., et al., Prevalence and risk factors for long COVID and post-COVID-19 condition in Africa: a systematic review. Lancet Glob Health, 2023. 11(11): p. e1713-e1724. 472 35. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect Dis, 2021. 21(1): p. 304. 474 36. Dryden, M., et al., Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. Lancet Glob Health, 2022. 10(9): p. e1247-e1256. 476 37. Moyo, E., et al., Risk factors and clinical presentations of long COVID in Africa: A scoping review. Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 		33.	
 Africa: a systematic review. Lancet Glob Health, 2023. 11(11): p. e1713-e1724. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect Dis, 2021. 21(1): p. 304. Dryden, M., et al., Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. Lancet Glob Health, 2022. 10(9): p. e1247-e1256. Moyo, E., et al., Risk factors and clinical presentations of long COVID in Africa: A scoping review. Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 			
 35. Osikomaiya, B., et al., 'Long COVID': persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect Dis, 2021. 21(1): p. 304. 36. Dryden, M., et al., Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. Lancet Glob Health, 2022. 10(9): p. e1247-e1256. 37. Moyo, E., et al., Risk factors and clinical presentations of long COVID in Africa: A scoping review. Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 		34.	
 473 Lagos State, Nigeria. BMC Infect Dis, 2021. 21(1): p. 304. 474 36. Dryden, M., et al., Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in 475 South Africa: a prospective cohort study. Lancet Glob Health, 2022. 10(9): p. e1247-e1256. 476 37. Moyo, E., et al., Risk factors and clinical presentations of long COVID in Africa: A scoping review. 477 Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 			
 474 36. Dryden, M., et al., <i>Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in</i> 475 <i>South Africa: a prospective cohort study.</i> Lancet Glob Health, 2022. 10(9): p. e1247-e1256. 476 37. Moyo, E., et al., <i>Risk factors and clinical presentations of long COVID in Africa: A scoping review.</i> 477 Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 		35.	
 South Africa: a prospective cohort study. Lancet Glob Health, 2022. 10(9): p. e1247-e1256. Moyo, E., et al., <i>Risk factors and clinical presentations of long COVID in Africa: A scoping review.</i> Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 		26	
 476 37. Moyo, E., et al., <i>Risk factors and clinical presentations of long COVID in Africa: A scoping review.</i> 477 Journal of Infection and Public Health, 2023. 16(12): p. 1982-1988. 		36.	
477 Journal of Infection and Public Health, 2023. 16 (12): p. 1982-1988.		27	
		37.	
AZO DO ZULU LE stal. Two weath fallow we of a suspense with CADC Call O infastion Zauchin Contauchen		20	
		38.	Zulu, J.E., et al., Two-month follow-up of persons with SARS-CoV-2 infection-Zambia, September
479 2020: a cohort study. Pan Afr Med J, 2022. 41 : p. 26.		20	
 480 39. Mulenga, L.B., et al., <i>Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-</i> 481 sectional cluster sample survey. Lancet Glob Health, 2021. 9(6): p. e773-e781. 		39.	
481 Sectional cluster sample survey. Lancet Glob Health, 2021. 9(6). p. e775-e781. 482 40. Sheppard, R.J., et al., Using mortuary and burial data to place COVID-19 in Lusaka, Zambia		40	, , , , , , , , , , , , , , , , , , , ,
482 40. Sheppard, K.J., et al., <i>Osing mortuary and bandratatic to place COVID-19 in Lusaka, 20mbia</i> 483 <i>within a global context.</i> Nat Commun, 2023. 14 (1): p. 3840.		40.	
484 41. Gill, C.J., et al., What is the prevalence of COVID-19 detection by PCR among deceased		<i>/</i> 1	
484 41. Gin, C.S., et al., what is the prevalence of COVID-19 detection by PCN unlong deceased 485 individuals in Lusaka, Zambia? A postmortem surveillance study. BMJ Open, 2022. 12 (12): p.		41.	
486 e066763.			
		42	Heilmann, E., et al., SARS-COV-2 seroprevalence trend among pregnant women in Zambia, 2021-
488 2022, in Conference on Retroviruses and Opportunistic Infections (CROI). 2023: Seattle,		72.	
489 Washington.			
0		43.	Mumba, T.K., et al., Seroprevalence survey of SARS-CoV-2, community behaviors, and practices in
491 <i>Kansanshi and Kalumbila mining towns.</i> Frontiers in Public Health, 2023. 11 .			
		44.	Shanaube, K., et al., SARS-CoV-2 seroprevalence and associated risk factors in periurban Zambia:
493 <i>a population-based study</i> . Int J Infect Dis, 2022. 118 : p. 256-263.			
494 45. Lewis, H.C., et al., SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of		45.	
495 standardised seroprevalence studies, from January 2020 to December 2021. BMJ Glob Health,			
496 2022. 7 (8).			
497 46. Ministry of Health (Zambia). <i>Clinical Guidance for Management of Patients with Coronavirus</i>		46.	
498 <i>Disease 2019 (COVID-19)</i> . 2020 [cited 2023 12 August]; Available from:			
499 <u>https://www.moh.gov.zm/?wpfb_dl=181</u> .	499		• • • •

- 47. Ministry of Health, *Clinical and Operational Guidelines for the Management of Post-Acute Covid-*501 *19 (PAC-19) Patients in Zambia*, in *Post-Acute COVID-19 Clinical and Operational Guidelines*.
 502 2022, Ministry of Health (Zambia): Lusaka.
- 50348.GISAID. EpiCov. 2023 [cited 2023 12 August]; Available from:504https://www.epicov.org/epi3/frontend#24d000.
- 50549.Charan, J. and T. Biswas, How to calculate sample size for different study designs in medical506research? Indian J Psychol Med, 2013. **35**(2): p. 121-6.
- 50750.Wong, R.S.Y., Inflammation in COVID-19: from pathogenesis to treatment. Int J Clin Exp Pathol,5082021. 14(7): p. 831-844.
- 509 51. Zhang, H.P., et al., *Recent developments in the immunopathology of COVID-19*. Allergy, 2023.
 510 78(2): p. 369-388.
- 51. 52. Fernández-de-las-Peñas, C., et al., *Prevalence of post-COVID-19 symptoms in hospitalized and* 512 *non-hospitalized COVID-19 survivors: A systematic review and meta-analysis.* European Journal
 513 of Internal Medicine, 2021. 92: p. 55-70.
- 51453.Cirulli, E.T., et al., Long-term COVID-19 symptoms in a large unselected population. medRxiv,5152020: p. 2020.10.07.20208702.
- 51654.Asadi-Pooya, A.A., et al., Risk Factors Associated with Long COVID Syndrome: A Retrospective517Study. Iran J Med Sci, 2021. 46(6): p. 428-436.
- 51855.Rane, M.S., et al., Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic519SARS-CoV-2 infections in an urgent care setting. Vaccine, 2023. 41(4): p. 989-998.
- 52056.Britton, A., et al., Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection521by Time Since Vaccination and Delta Variant Predominance. Jama, 2022. **327**(11): p. 1032-1041.
- 522 57. Chanda, D., et al., *COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in* 523 *Zambia, 2021-2022.* Open Forum Infect Dis, 2022. **9**(9): p. ofac469.

524

525